Affymetrix Provides Updates on Genotyping Growth, Biobank Deals, Expression Outlook in Q3 Call | GenomeWeb

This story was originally posted on Nov. 1.

Affymetrix executives offered more details about the firm's ongoing turnaround during the company's third quarter earnings call last week.

While CEO Frank Witney acknowledged on the call that the Santa Clara, Calif.-based company reported "modest" year-over-year growth of 1 percent in Q3, he said the firm believes that its "growth momentum" will continue, driven by new product offerings.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

Intelligence officials in the US have added gene editing to a list of weapons of mass destruction.

In Cell this week: characterization of functional genomic features in breast cancer cell lines, epigenetic pattern linked to obesity, and more.

President Obama's proposed budget for fiscal year 2017 includes an increase for NIH, but seeks some of it as mandatory funding.

Sure Genomics begins to offer direct-to-consumer genome sequencing for $2,500.